PreveCeutical Medical, Inc. engages in licensing, branding, and marketing of nutraceutical and wellness products. The company is headquartered in West Vancouver, British Columbia. The company went IPO on 2016-12-30. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, and BSV Peptide Program. Its Cannabinoid Sol-Gel is a cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its BSV peptide program targets cancer progression. Its nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). Its Nature Identical peptides used for treatment of various ailments. Its Dual Gene Therapy for curative and prevention therapies for diabetes and obesity.
Follow-Up Questions
PRVCF 주식의 가격 성능은 어떻습니까?
PRVCF의 현재 가격은 $0.0216이며, 전 거래일에 decreased 0% 하였습니다.
Preveceutical Medical Inc의 주요 사업 주제나 업종은 무엇입니까?
Preveceutical Medical Inc은 N/A 업종에 속하며, 해당 부문은 N/A입니다